Patents by Inventor Eun-Ji Koh

Eun-Ji Koh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10100010
    Abstract: The present invention provides a 4-methoxy pyrrole derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The 4-methoxy pyrrole derivatives or pharmaceutically acceptable salts thereof according to the present invention have not only excellent proton pump inhibitory activity, gastric damage-inhibiting activity and defensive factor-enhancing effects, but also excellent eradication activity against H. pylori. Therefore, the 4-methoxy pyrrole derivatives or pharmaceutically acceptable salts thereof can be effectively used for the prevention and treatment of gastrointestinal damage due to gastrointestinal tract ulcer, gastritis, reflux esophagitis or H. pylori.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: October 16, 2018
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Chun Ho Lee, Seung Chul Lee, Yeon Im Lee, Deok Ki Eom, Mi Ryeong Han, Eun Ji Koh
  • Patent number: 9724336
    Abstract: Provided is a pharmaceutical composition for preventing or treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt; and an angiotensin II receptor blocker as active ingredients.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: August 8, 2017
    Assignee: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Jong-Wook Lee, Sang-Ho Lee, Taek-Joo Lim, Eun-Ji Koh
  • Patent number: 9486443
    Abstract: The present invention is a method for treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt and amlodipine or its pharmaceutically acceptable salt at a synergistic ratio of about 4:1.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: November 8, 2016
    Assignee: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Jong-Wook Lee, Sang-Ho Lee, Taek-Joo Lim, Eun-Ji Koh
  • Publication number: 20140336229
    Abstract: Provided is a pharmaceutical composition for preventing or treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt; and an angiotensin II receptor blocker as active ingredients.
    Type: Application
    Filed: November 28, 2012
    Publication date: November 13, 2014
    Applicant: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Jong-Wook Lee, Sang-Ho Lee, Taek-Joo Lim, Eun-Ji Koh
  • Publication number: 20140336228
    Abstract: Provided is a pharmaceutical composition for preventing or treating hyperlipidemia comprising (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-({2-[4-fluoro-2-methoxy-5-(propan-2-yl)phenyl]-5-(trifluoromethyl)phenyl}methyl)-4-methyl-1,3-oxazolidin-2-one or its pharmaceutically acceptable salt; and a calcium channel blocker or a fibrate as active ingredients.
    Type: Application
    Filed: November 28, 2012
    Publication date: November 13, 2014
    Applicant: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: Jong-Wook Lee, Sang-Ho Lee, Taek-Joo Lim, Eun-Ji Koh